普利制药(300630.SZ):注射用比伐芦定、左氧氟沙星片拟中标第四批全国药品集采
格隆汇 2 月 3日丨普利制药(300630.SZ)公布,2021年02月03日,公司及其全资子公司浙江普利药业有限公司(“浙江普利”)参加了国家组织药品集中采购和使用联合采购办公室组织的第四批全国药品集中采购。
公司与浙江普利的注射用比伐芦定、左氧氟沙星片已获得国家药品监督管理局化学药品4类的注册批件,参加了此次集中采购并拟中选。
此次拟中标的药品如确认中标,医疗机构将优先使用此次药品集中采购中选药品,并确保完成约定采购量。此次公司拟中标第四批全国药品集中采购,后续签订采购合同并实施后,将有利于促进公司相关产品的销售,提高市场占有率,提升品牌影响力,对公司的未来经营业绩产生积极的影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.